{
  "schema_version": 1,
  "kind": "drug_profile",
  "generic": "bupropion",
  "review_status": "reviewed",
  "origin": "openfda",
  "sections": {
    "adult": [
      {
        "text": "( 2.2 ) Major Depressive Disorder Starting dose: 150 mg once daily.",
        "source": "US FDA label for bupropion (Bupropion Hydrochloride), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/bupropion.json",
        "verbatim": true
      },
      {
        "text": "Usual target dose: 300 mg once daily ( 2.2 ) After 4 days, may increase the dose to 300 mg once daily.",
        "source": "US FDA label for bupropion (Bupropion Hydrochloride), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/bupropion.json",
        "verbatim": true
      },
      {
        "text": "( 2.3 ) Starting dose: 150 mg once daily.",
        "source": "US FDA label for bupropion (Bupropion Hydrochloride), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/bupropion.json",
        "verbatim": true
      }
    ],
    "child": [
      {
        "text": "Safety and effectiveness in the pediatric population have not been established. When considering the use of bupropion hydrochloride extended-release tablets (XL) in a child or adolescent, balance the potential risks with the clinical need [see BOXED WARNING and WARNINGS AND PRECAUTIONS ( 5.1 )].",
        "source": "US FDA label for bupropion (Bupropion Hydrochloride), section 'pediatric use', retrieved 2026-08-29",
        "cached_file": "labels/bupropion.json",
        "verbatim": true
      },
      {
        "text": "General: Increase dose gradually to reduce seizure risk. ( 2.1 , 5.3 ) Periodically reassess the dose and need for maintenance treatment. ( 2.2 ) Major Depressive Disorder Starting dose: 150 mg once daily. Usual target dose: 300 mg once daily ( 2.2 ) After 4 days, may increase the dose to 300 mg once daily. ( 2.2 ) Seasonal Affective Disorder Initiate treatment in the autumn prior to onset of seasonal depressive symptoms.",
        "source": "US FDA label for bupropion (Bupropion Hydrochloride), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/bupropion.json",
        "verbatim": true
      }
    ],
    "renal": [
      {
        "text": "( 2.6 , 8.7 ) Renal Impairment Consider reducing the dose and/or frequency of dosing.",
        "source": "US FDA label for bupropion (Bupropion Hydrochloride), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/bupropion.json",
        "verbatim": true
      },
      {
        "text": "Because elderly patients are more likely to have decreased renal function, it may be necessary to consider this factor in dose selection; it may be useful to monitor renal function [see DOSAGE AND ADMINISTRATION ( 2.7 ), USE IN SPECIFIC POPULATIONS ( 8.6 ), and CLINICAL PHARMACOLOGY ( 12.3 )].",
        "source": "US FDA label for bupropion (Bupropion Hydrochloride), section 'use in specific populations', retrieved 2026-08-29",
        "cached_file": "labels/bupropion.json",
        "verbatim": true
      }
    ],
    "hepatic": [
      {
        "text": "( 2.3 ) Hepatic Impairment Moderate to severe hepatic impairment: 150 mg every other day ( 2.6 ) Mild hepatic impairment: Consider reducing the dose and/or frequency of dosing.",
        "source": "US FDA label for bupropion (Bupropion Hydrochloride), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/bupropion.json",
        "verbatim": true
      },
      {
        "text": "Monitor closely for adverse reactions that could indicate high bupropion or metabolite exposures [see DOSAGE AND ADMINISTRATION ( 2.7 ) and CLINICAL PHARMACOLOGY ( 12.3 )]. 8.7 Hepatic Impairment In patients with moderate to severe hepatic impairment (Child-Pugh score: 7 to 15), the maximum bupropion hydrochloride extended-release tablets (XL) dose is 150 mg every other day.",
        "source": "US FDA label for bupropion (Bupropion Hydrochloride), section 'use in specific populations', retrieved 2026-08-29",
        "cached_file": "labels/bupropion.json",
        "verbatim": true
      },
      {
        "text": "In patients with mild hepatic impairment (Child-Pugh score: 5 to 6), consider reducing the dose and/or frequency of dosing [see DOSAGE AND ADMINISTRATION ( 2.6 ) and CLINICAL PHARMACOLOGY ( 12.3 )].",
        "source": "US FDA label for bupropion (Bupropion Hydrochloride), section 'use in specific populations', retrieved 2026-08-29",
        "cached_file": "labels/bupropion.json",
        "verbatim": true
      }
    ],
    "pregnancy": [
      {
        "text": "Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antidepressants during pregnancy.",
        "source": "US FDA label for bupropion (Bupropion Hydrochloride), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/bupropion.json",
        "verbatim": true
      },
      {
        "text": "Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Antidepressants at 1-844-405-6185 or visiting online at https://womensmentalhealth.org/clinical-and-researchprograms/pregnancyregistry/antidepressants/.",
        "source": "US FDA label for bupropion (Bupropion Hydrochloride), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/bupropion.json",
        "verbatim": true
      },
      {
        "text": "Risk Summary Data from epidemiological studies of pregnant women exposed to bupropion in the first trimester have not identified an increased risk of congenital malformations overall (see Data).",
        "source": "US FDA label for bupropion (Bupropion Hydrochloride), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/bupropion.json",
        "verbatim": true
      }
    ],
    "lactation": [
      {
        "text": "Risk Summary Data from published literature report the presence of bupropion and its metabolites in human milk (see Data).",
        "source": "US FDA label for bupropion (Bupropion Hydrochloride), section 'nursing mothers', retrieved 2026-08-29",
        "cached_file": "labels/bupropion.json",
        "verbatim": true
      },
      {
        "text": "There are no data on the effects of bupropion or its metabolites on milk production.",
        "source": "US FDA label for bupropion (Bupropion Hydrochloride), section 'nursing mothers', retrieved 2026-08-29",
        "cached_file": "labels/bupropion.json",
        "verbatim": true
      },
      {
        "text": "Limited data from postmarketing reports have not identified a clear association of adverse reactions in the breastfed infant.",
        "source": "US FDA label for bupropion (Bupropion Hydrochloride), section 'nursing mothers', retrieved 2026-08-29",
        "cached_file": "labels/bupropion.json",
        "verbatim": true
      }
    ]
  }
}